BRAF and differentiated thyroid carcinoma: Besides, Bai et al. have revealed that the expression of BRAF V600E showed positive association with PD-L1/PD-1 in papillary thyroid carcinoma (PTC) samples, suggesting that immunotherapies that target PD-L1/PD-1 might be effective in PTC patients with BRAF V600E mutation [14].